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Abstract 
This project is a part of the development of biomaterials for bone tissue engineering for type 2 
diabetic patients. The latters show a higher rejection implant rate than healthy people.  
When people are affected by type 2 diabetes they develop insulin resistance and the glucose 
accumulates in blood. Hyperglycemia leads to the ROS (reactive oxygen species) production.  
The ROS takes part of an equilibrium (redox biology). They are used by cells in several mechanisms 
such as signal transduction, cellular proliferation or differentiation and development. However if they 
are overproduced, they become cytotoxic and leads to oxidative stress.   
ROS have an impact on bone remodeling and enhance the resorption of bones. In the case of 
implant, a local treatment of ROS is needed to help the bone to form around the implant. To 
counterbalance the oxidative stress from the ROS, the nifedipine will be used for its anti-oxidative 
properties. But this drug is light sensitive and poorly soluble in water and it affects its bioavailability. 
To protect it and have a local treatment, silica mesoporous nanoparticles are used. Thanks to their 
high surface area and their high pore volume, it is possible to load a large quantity of drug inside the 
pores via adsorption. And the nanoparticles can bring a protection to the drug. 
The aims of the project is to chose the best way to load nanoparticles among different methods and 
to choose a release method between three ones.  
The first step of this project has been the synthesis of nanoparticles. The technique used is a sol-gel 
process where silica is obtained by the hydrolysis of TEOS on CTAB in a basic medium. A co-
condensation was driven with APTES, the functionalization.  
The second step was the loading of the nanoparticles with nifedipine. Four methods have been 
studied. The characterization has been done by Fourier transform infrared spectroscopy (FTIR) and 
thermogravimetric analysis (TGA). The FTIR gives evidence of the presence of nifedipine and the TGA 
allows to quantify it. The results show different percentage of loading which depend on the method 
used. 
The third step was to study the release of nifedipine. Three different methods have been used: 
dialysis, USP apparatus and tubes. The characterization of the release has been processed by UV-vis 
NIR spectrophotometry at 238 nm. The three methods show a release of the drug but one is 
preferred.  
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Glossary 
Name Abbreviation 
Cetyltrimethylammonium bromide CTAB 
Tetraethyl orthosilicate TEOS 
(3-Aminopropyl)triethoxysilane APTES 
Nifedipine Nif 
Mesoporous silica nanoparticles functionalized 
with 2 mL of APTES 
MSN-2-NH2 
Mesoporous silica nanoparticles functionalized 
with 2 mL of APTES loaded with Nifedipine 
MSN-2-NH2-Nif 
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1. State of the art  
This project is a part of the development of biomaterials for bone tissue engineering for type 2 
diabetic patients. These latter show a higher rejection implant rate than healthy people. The aim is to 
bring a local treatment , in the border of the implant, to help the oragnism to accept the implant. 
 
1. Type 2 Diabetes  
1) What is type 2 diabetes? 
The type 2 diabetes is the most present form of diabetes (about 90%). Most of the time it appears 
when people are adults (40-year-old and more). Unfortunately, more and more young people, even 
children, are affected by type 2 diabetes [1]. An OMS study shows that in 2014, 422 million of people 
were living with diabetes [2].  
Diabetes is a chronical disease which implicates insulin resistance and a case of obesity most of the 
time.  
In healthy people, all cells work with glucose. It is obtained by food or given by liver (out of meals 
during the night, for example). The glucose is driven to cells by way of blood. To penetrate cells, 
glucose needs help of a hormone which is produced by the beta cells in the pancreas: the insulin. The 
hormone attaches to the cell receptor which opens the gate, lets enter the glucose into the cell and 
leads to a decrease of glycemia (figure 1).  
In diabetic people, at the beginning of the disease, the insulin secretion by beta cells is normal. But 
the obesity state stimulates cells to take energy from fatty acids and no more from glucose, causing a 
resistance to insulin of the cells (figure 1).   
Therefore pancreatic islet cells produce more insulin to force cells to take it. With time the pancreatic 
cells have run through insulin, its production decreases then disappears and the glucose rate 
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Figure 1 Scheme of insulin and glucose intercations in normal working and in type 2 diabetes. [3] 
The type 2 diabetes, afterwards, can lead to complications such as skin infections, diabetic 
retinopathy, arteriosclerosis, heart damage, fatty liver, permanent kidney damage and osteoporosis 
(figure 2). 
 
Figure 2 Diabetes complications. [3] 
In the case of an implantation, the osteoporosis could give rise to difficulties in the osteointegration 
of the implant. 
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2) Glucose toxicity 
A chronic hyperglycemia, due to diabetes, affects all tissues [1] and targets different organs which 
leads to different secondary dysfunctions such as retinopathy, kidney failure, neuropathies or 
macrovascular diseases and more particularly to the cells apoptosis and necrosis [4]. Indeed glucose 
in excess causes toxic effects on organs.  
Different ways of this toxicity have in common the production of Reactive Oxygen Species (ROS) 
which cause oxidative stress and thus cell damage [5]. It has been proven that stable or intermittent 
high glucose level enhances oxidative stress generation [4]. A high oscillating glucose level is even 
more dangerous than a stable one. The antioxidative response of the cell is jeopardized, oxidative 
stress is increased which leads to cell apoptosis [4].   
Several ways have been reported to develop ROS from glucose (figure 3) [5]. 
 
Figure 3 Different pathways from glucose to ROS.[5] 
Pathway 1: enolization and α-ketoaldehyde formation. In the presence of redox active metals, H2O2 
can form the toxic hydroxyl radical (it causes mutagenic alterations in DNA). 
Pathway 2: PKC activation. It has biochemical consequences such as microvascular diseases in 
diabetes. 
Pathway 3: dicarbonyl formation and glycation.  
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Pathway 4: sorbitol metabolism  
Pathway 5: hexosamine metabolism. It is implicated in insulin resistance and in the rise of hydrogen 
peroxide levels.  
Pathway 6: oxidative phosphorylation. It increases the superoxide production by a stimulation of 
mitochondrial activity. 
Here, it is easily understandable that the increase of glucose leads to the rise of ROS. 
The oxidative stress impairs beta cells function as well. The glucotoxicity has an influence on the 
insulin gene expression, decreases the insulin content and the insulin secretion [1], [5]. Under high 
glucose exposure, the beta islet cells show an increased cell apoptosis. Moreover, the beta cells show 
the lowest levels of antioxidant enzyme compared with other cells [1].   
Also the endothelial cells are victims of diabetes complications [4].  
 
2. Reactive Oxygen Species 
1) What are they? 
ROS is an acronym standing for Reactive Oxygen Species. This name represents different molecules 
and free radicals derived from oxygen.  
Atomic oxygen possesses two unpaired electrons in the valance electrons. Thus, it is possible for 
oxygen to form radicals. The different steps of the reduction of oxygen leads to the formation of 
several ROS such as superoxide anion, peroxide, hydrogen peroxide, hydroxyl radical or hydroxyl ion 
(figure 4). 
 
Figure 4 Oxygen and different Reactive Oxygen Species. [6] 
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Most of the time they are by-products of the mitochondrial electron transport respiration, 
oxidoreductase enzymes or metal catalyzed oxidation. These molecules are responsible for lots of 
harmful effects.  
The mitochondria are the most productive source of ROS (95% of ROS at cellular level under 
physiological condition). The majority of ROS are derived from the superoxide anion 𝑂2
− . which is 
produced by the mitochondrial electron transport respiration. Almost all the superoxide anions are 
converted to hydrogen peroxide 𝐻2𝑂2 by a dismutation reaction due to an enzyme, the superoxide 
dismutase (SOD) (figure 5). [7] 
 
 
Figure 5 Origin of mitochondrial ROS. The yellow arrows represent the enzymatic detoxification SOD: superoxide 
dismutase, GPx: glutathione peroxidase. [7] 
 
𝐻2𝑂2 can be neutralized by antioxidant defense (GPx, catalase) to water but a part follows the 
Haber-Weiss reaction and forms hydroxyl radical 𝑂𝐻. .The reaction is catalyzed in the presence of 
metallic ions and gives the Fenton reaction.  
Free radicals possess an unpaired electron on the last molecular orbital which give them a high 
reactivity. They are represented with a dot on the figure 5. 
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Table 1 Properties (t1/2, migration distance), reactivity (mode of action), formation (typical production systems), and 
scavenging (typical scavenging systems) of ROS in plant and animal cells. Abbreviations: APX, ascorbate peroxidase; 
CAT, catalase; GPX, glutathione peroxidase; PER, peroxidase; PRX, peroxiredoxin; RBOH, respiratory burst oxidase 
homolog; SOD, superoxide dismutase.  [8] 
 
2) The ROS take part of an equilibrium.  
ROS take part of an equilibrium between production and elimination (figure 6).  
 
 
Figure 6 ROS equilibrium, between health and disease. [8] 
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If the redox biology is not respected, organism is threatened as it can be seen on the figure 6 
(cytotoxicity).  
ROS have a role in different mechanisms for example in phagocytic cells, in signal transduction or for 
the Redox signaling [8].  
Phagocytic cells produce ROS for the bactericidal action. The production of ROS by phagocytes was 
originally called ‘the respiratory burst’ because of the rise of oxygen consumption. This process is 
helped by NADPH oxidase which is a complex enzyme. It is another big producer of ROS. 
ROS also play a role in signaling transduction, for example nitric oxide is known to be a cell-to-cell 
messenger which affects blood pressure. Intra cellular ROS in conjunction with antioxidant enzymes 
play a role in the enzyme activity by turning it on or off with redox reactions.  
ROS are required in the mitogenic signaling (relative to mitosis or the cellular division). For instance 
hydrogen peroxide is useful for the proliferation in response to growth factors. 
When the cells proliferate, they follow a procedure, the cell cycle. There are several steps and 
different checkpoints. Each of them is regulated by proteins that are influenced by the oxidative state 
of the cell. The apoptosis of the cells is also promoted by ROS. In brief, ROS control the cell cycle via 
redox signaling. 
But ROS can become dangerous for cells if they are present for a too long time. Organism has also its 
own defense mechanisms against ROS such as superoxide dismutase, glutathione and catalase [6], 
[39]. This provide the balance of ROS between production and elimination. An imbalanced state in 
favor of ROS is called the oxidative stress.  
A mechanism of defense is the superoxide dismutase (SOD) which catalyzes the conversion of two 
superoxide anions into hydrogen peroxide and oxygen (Eq 1). After that cells convert H2O2 to water 
and oxygen which finishes the detoxification (Eq 2).  
      2 𝑂2
− + 2 𝐻+ →  𝐻2𝑂2 +  𝑂2                                                    (𝐸𝑞 1) 
2 𝐻2𝑂2  → 2 𝐻2O +  𝑂2                                                (Eq 2) 
The glutathione (GSSG), a group of enzymes, catalyzes the degradation of hydrogen peroxide to 
water (Eq 3) and organic peroxides to alcohols (Eq 4). It is the most important intra-cellular defense 
against ROS. The GSSG reduced form (GSH) is regenerated via a redox reaction by NADPH (Eq 5). A 
good indicator of the oxidative stress is the ratio of oxidized form of glutathione (GSSG) and the 
reduced form (GSH). 
2 𝐺𝑆𝐻 +  𝐻2𝑂2  → 𝐺𝑆𝑆𝐺 + 2 𝐻2𝑂                                    (𝐸𝑞 3) 
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2 𝐺𝑆𝐻 + 𝑅𝑂𝑂𝐻 → 𝐺𝑆𝑆𝐺 + 𝑅𝑂𝐻 +  𝐻2𝑂                         (𝐸𝑞 4) 
𝐺𝑆𝑆𝐺 + 𝑁𝐴𝐷𝑃𝐻 +  𝐻+  → 2 𝐺𝑆𝐻 +  𝑁𝐴𝐷𝑃+                   (𝐸𝑞 5) 
The catalase is an enzyme which degrades the hydrogen peroxide into water and oxygen (Eq 6). 
2 𝐻2𝑂2  → 2 𝐻2𝑂 +  𝑂2                                            (𝐸𝑞 6) 
Vitamin C, soluble in water, is able to reduce ROS and vitamin E which is soluble in lipids has the same 
effects regarding ROS but it takes place in the membrane.   
 
3. Bone disorder under diabetic mellitus 
The life of bones is governed by remodeling. The bone tissue is alive and dynamic (formation, growth, 
mineral homeostasis…), thanks to osteoblasts and osteoclasts. They are responsible for the formation 
and the resorption of bone tissues respectively.  
Bone mineral density is modulated by the osteoclasts, responsible for the bone resorption, and the 
osteoblasts which fill the cavities of osteoclasts. The osteoclasts dissolve the mineral part of the bone 
and enzymes dissolve the collagen part. After that, osteoblasts deposit organic matter (collagen and 
enzymes) where minerals (calcium, phosphate) crystalize. 
The interaction between osteoblasts and osteoclasts is governed by ligand, receptor and protein. 
The pre-osteoblasts (and osteoblasts) express a ligand, RANKL, and the pre-osteoclasts have a 
receptor, RANK. The ligand RANKL binds to pre-osteoclasts thanks to the ligand-receptor bond. This 
binding is a message for the pre-osteoclasts to multiplicate and fusion. This results to the formation 
of mature osteoclasts. Once the action of osteoclasts is done, pre-osteoblasts express a protein, the 
osteoprotegerin, which binds to the RANKL (preventing the bond RANK/RANKL). The pre-osteoblasts 
differentiate to osteoblasts and allow to fill the cavities of the osteoclasts (figure 7). After the bone 
remodeling, the osteoblasts can differentiate in osteocytes (bone cells) or in border cells (which cover 
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Figure 7 Bone remodeling under oxidative stress. [40] 
However, under oxidative stress, the interaction between osteoblasts and osteoclasts is unbalanced 
and the bone formation is altered. The osteoblastogenesis is decreased whereas the 
osteoclastogenesis is increased. Under oxidative stress, osteoblasts produce more RANKL, increasing 
the osteoclasts differentiation and activities.  
An equilibrium exists between formation and resorption. But with age, the activity of osteoclasts is 
predominant. The equilibrium is broken and it leads to a loss of bone density. 
People affected by diabetes present an increased risk of fracture due to a higher level of oxidative 
stress. In vivo experiments show osteopenia (decrease of bone mineral density) with an increased 
level of oxidative stress.   
Diabetes increases bone fracture and decreases bone healing and bone turnover by reducing the 
bone mass. One hypothesis of this, is the diabetes-induced increase in ROS. In type 2 diabetes, 
osteopenia is an effect of decreased mineralization. Type 2 diabetes decreases bone strength and 
bone mineral density, the bone fragility is highly connected to the presence of advanced glycation 
end-products (AGEs) in bone collagen[41]. AGEs are at the origin of the formation of oxidative stress.
  
In the case of implantation, a local treatment could be proposed to counterbalance the action of ROS. 
To enhance osteointegration an antioxidant could be used.  
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4. Nifedipine 
1) Properties 
Nifedipine is a yellow, odorless, tasteless, non-hygroscopic crystalline powder. Its formula is 
C17H18N2O6 (figure 8) and its moecular weigth is 346,3 g/mol. Its melting point is between 172 and 
174 °C [9].  
 
Figure 8 Nifedipine formula and dimension. [10]  
The nifedipine is soluble in different solvents such as acetone, methanol or ethanol. But it is poorly 
soluble in water and in PBS (table 2) [9], [11].  
Table 2 Nifedipine solubility 
Solvent Solubility 
Acetone (20°C) 250 mg/mL 
Methylene chloride (20°C 160 mg/mL 
Chloroform (20°C) 140 mg/mL 
Ethyl acetate (20°C) 50 mg/mL 
DMSO 50 mg/mL 
Methanol (20°C) 26 mg/mL 
Ethanol (20°C) 17 mg/mL 
Water 0,02 mg/mL 
PBS (pH 7) 5,6 mg/L or 0,0056 mg/mL 
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Here is an infrared spectrum of nifedipine (figure 9) following by the correspondence frequencies-





Figure 9 Nifedipine IR spectra and correlation between structural assignments and band frequencies. [12] 
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An example of an ultraviolet spectra of the nifedipine is given figure 10. The spectra have been 
processed with methanol (absorption maxima at 235 and 340 nm), HCl (maximum absorption at 238 
nm) and NaOH (maximum absorption at 340).  
A study has used the UV-vis spectrophotometry to analyze the nifedipine in PBS. The nifedipine 
shows a maximum at 238 nm using this solvent [43]. 
 
 
Figure 10 UV spectra of Nifedipine in different solvents. [12] 
The nifedipine is a sensitive molecule. Light, elevated temperature and presence of oxidizing agent 
can degrade the nifedipine [13]. 
Under these conditions, nifedipine leads to two derived compounds: nitroso nifedipine, NO-NIF (I) 
and nitro nifedipine, (II) (figure 11). The photo stability of the drug depends on the irradiation 
wavelength, the time exposure, the intensity and the state of the formulation (solid or liquid). 
Nifedipine in solution is much more sensitive to light than in its solid form. Nifedipine is highly 
sensitive to UV-vis radiation up to 450 nm with a maximum at 380 nm with a quantum yield of about 
0.5. The molecule seems to degrade following a first order reaction [13]. 
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Figure 11 Derived compounds of nifedipine. [13] 
 
The quantum yield corresponds to the number of chemical species that undergo reaction per photon 
of absorbed radiation of a given energy.  
The stability of nifedipine under different source lights have already been studied (figure 12).  
A solution of nifedipine (0,01%) in alcohol was kept exposed to daylight. At the beginning, the 
solution was yellow and turned colorless. The nitroso compound was formed with a new absorption 
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Figure 12 Decomposition parameter (k, t50 and t90) of nifedipine in alcoholic solution; photodegradation with different 
light sources. [12] 
In this table are given k, the rate constant, t50, the time required for the nifedipine to reduce to half 
its initial concentration and t90, the time corresponding to 10% of decomposed nifedipine.  
Here, it is visible that the decomposition of nifedipine in solution under light is quite fast.  
2) Medicine 
 
 Calcium channel blocker 
Calcium channel blockers (CCB) or calcium antagonists inhibit the entrance of calcium (𝐶𝑎2+) into 
cells. This kind of drug is mainly used to treat heart diseases or high blood pressure. Nifedipine is 
a derivate from dihydropyridine and is a L-type channel blocker (figure 13 a)). 
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Figure 13 a) and b) : Classification of calcium channel blockers and Classical effect of L-type CCB : amlodipine [14]. 
Calcium ions are vital for biologic processes such as enzymatic reaction and metabolism of bones. The 
blocking effect of calcium antagonists is voltage-dependent, the blocking is more effective when the 
membrane is depolarized as voltage gate calcium channels are opened [15].   
There are several kinds of calcium channel blockers: L-type for long lasting, large channel, N-type for 
neural, P-type for purkinje cells (neurons) and T-type for transient, tiny channel. There are at least 
two classifications, one which considers the percentage of inhibition and the other one the affected 
cells. 
The mechanism of action can produce two effects, either a physical obstruction or a distortion of the 
membrane through a nonspecific interaction [15]. 
Apparently, dihydropyridine compounds bind to proteins (figure 13 b)) and cause an obstruction 
because of a physical connection but it seems to be more difficult than this (some dihydropyridines 
bind to the same site but act totally differently and open the gate) [15].  
Channels, where dihydropyridines bind to, exist in different modes: 0 (channel does not open in 
response to a depolarization), 1 (depolarization produces low and brief opening) and 2 
(depolarization produces a very high and prolonged openings). Dihydropyridines bind selectively to 
channel in mode 0 which favor a non-opening state [15].    
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 Antioxidant 
 
Figure 14 Schematic of the antioxidative activity of a lipophilic CCB: amlodipine [14]. 
Previous studies have shown the antioxidant properties of nifedipine. For example in cardiovascular 
diseases, the calcium blockers may provide antiperoxidative protection to cardiac membranes 
(cardiovascular diseases are due to the presence of free radicals in the membrane) [16]. Other 
studies highlighted the effects of several beta-blockers, whose nifedipine took part, on free radical 
injury in endothelial cells [17]; and the effect of short or long-term treatment of endothelium with 
dihydropyridine calcium antagonists which results in an increase in oxide nitrite [18]. The 
antioxidative behavior of nifedipine is independent of the calcium channel blocking activity. 
The antioxidant capacity of dihydropyridine compounds can be due to aromatic unsaturated ring 
moieties which provides a resonance stabilization for trapped radicals. The radicals can be 
neutralized by a hydrogen transfer or electron donating mechanism.     
In the case of nifedipine, it contains an electron rich dihydropyridine moiety. Thus the antioxidant 
action may be mediated by an electron transfer process [17].   
The antiperoxidative activity is correlated with the lipid solubility [14].   
Lipid peroxidation can be also prevented by dihydropyridine drugs (figure 14). The prevention is 
related to the lipophilicity and the chemical structure of the drug. The structure facilitates proton-
donating and resonance-stabilization mechanisms quench the free-radical reaction. More precisely, 
highly lipophilic CCBs are capable of donating protons to lipid peroxide molecules and thus blocking 
the peroxidation process (Eq 7). The free electron associated with the drug molecule can be stabilized 
in resonance structures thanks to the dihydropyridine ring.  
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                                                           LOO• +DHP -> LOOH + DHP•                                                       (Eq 7) 
 
with LOO• the lipid peroxide molecule and DHP dihydropyridine.[14] 
 
 Nitroso compound 
The derivative compounds of nifedipine were evaluated as toxic because they don’t provide the 
calcium channel blocking effect.   
However it has been shown that the derived compound from nifedipine has antioxidant properties. 
The nitroso nifedipine (compound I, figure 11), (2,6-dimethyl-4-(2-nitrosophenyl)-3,5-pyridine-
dicarboxylic acid dimethyl ester) does not show hypertensive activity but antioxidant one. NO-NIF is 
accumulated in the membrane and converted to NO-NIF radicals. This seems to give a good 
protection against ROS, even better than some antioxidant (Trolox C, an antioxidant similar to 
vitamin E) (figure 15). Moreover, NO-NIF can be produced enzymatically without exposure to light 
[19].  
 
Figure 15 Protective effect on NO-NIF on Cum-OOH. [19] 
This graph compares the antioxidant activity of Nifedipine, NO-NIF and Trolox-C against ROS (Cum-




Nifedipine has been shown to improve cognitive functions in type 2 diabetes [20].   
The drug shows an attenuation of hyperinsulinemia, which downregulates insulin receptors and 
reduces transport into the brain causing cognitive decline. Nifedipine could attenuate insulin 
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resistance and superoxide anions in the brain. Both are linked because oxidative stress increases 
insulin resistance. 
Dihydropyridine can also be used to treat diabetic nephropathy, renal diseases which affect type 1 
and type 2 diabetic people. These drugs allow a vasodilation of arterioles and has beneficial effects in 
term of reducing proteinuria (protein leakage in the kidney which is an evidence of an unhealthy 
kidney) and slowing the progression of diabetic renal failure [15]. 
Nevertheless, for the implant treatment, the drug could not be orally administered. The treatment 
will be localized near the implant. As the implant can not be simply recovered with the drug, carriers 
are needed. Moreover the carriers could protect the drug from degradation.  
 
5. Nanoparticles 
Nifedipine is a poorly water-soluble calcium channel blocker drug. Due to insolubility, nifedipine 
possesses a low bioavailability. To overcome both problems, one strategy is to use an excipient to 
improve the dissolution of the drug like a polymer nanosuspension, polymeric nanocapsules, or 
mesoporous silica as drug delivery carriers (drug adsorbs into mesopores) [1]. In this project, we will 
focus on mesoporous silica nanoparticles. This kind of material shows a high specific area and large 
pore volume. These two parameters will contribute to the efficiency of the drug loading.   
 
The main idea is to load the nifedipine inside the particles thanks to a solvent via adsorption. And 
then the drug will be released.   
This strategy has been already reported on bibliography  [10], [21], [22], [23], [24]. 
1) Synthesis 
The synthesis is based on a sol-gel procedure. The nanoparticle structure is obtained from a 
surfactant. In this study, cetyltrimethylammonium bromide (CTAB), is used (figure 16). 
 
Figure 16 CTAB formula. 
This kind of molecule is amphiphile, that is, with a hydrophobic part and a hydrophilic part (figure 17 
a)). In water, these molecules organize themselves in micelles (figure 17 b)) to minimize the repulsive 
interactions between the hydrophobic part and water. Thus, hydrophobic parts gather and micelles 
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are formed.  
They are obtained spontaneously from the critical micellar concentration (the smallest concentration 
needed to form micelles).  
 
Figure 17 a) Surfactant and b) micelle morphology. [25] 
The critical concentration is characteristic of each surfactant and depends on the temperature and 
the presence of additive in the reactive medium.  
The experimental setups are very important because the form of the micelle depends on it. The 
structures adopted by the micelles can be spherical, cubic, lamellar or hexagonal (figure 18).  
 
Figure 18 CTAB/water phase diagram, Temperature versus surfactant fraction. L1: isotropic liquid, H1: hexagonal phase, 
V1: cubic phase, Lα: lamellar phase, S: surfactant crystals. [26] 
In this project, hexagonal structures are synthesized. 
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After the formation of the micelles, the silica skeleton is formed from the hydrolysis reaction of 
tetraethyl orthosilicate (TEOS, figure 19). The interaction between CTAB and TEOS is possible thanks 
to the head positively charged of CTA+ and Si-O- groups.  
 
Figure 19 TEOS formula. 
The formation of the nanoparticles follows three reactions: hydrolysis, alcohol condensation and 
water condensation (figure 20). During the first steps (hydrolysis and condensations) a solution of 
colloidal silica is obtained. As and when the siloxane (Si-O-Si) groups appear, a gel is formed. And 
finally, to obtained powder, the gel is dried and calcined. 
 
 
Figure 20 Different steps of the synthesis of nanoparticles. [27] 
It is also possible to do hybrid mesoporous materials by functionalyzing nanoparticles. The 
functionalization can be done directly during the synthesis of the nanoparticles, in this case it is a co-
condensation reaction. Or it can be achieved after the synthesis of the nanoparticles.  
In this project, the nanoparticles have been functionalized by co-codensation. The functionalizing 
agent used was the (3-Aminopropyl)triethoxysilane (APTES, figure 21). 
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Figure 21 APTES formula. 
Once the nanoparticles formed, the pores need to be cleared of CTAB. Indeed, CTAB is toxic and it 
fills the pores so the drug can not be loaded. The surfactant can be removed by calcination or by 
several washings with a solvent (such as ethanol) or by ion exchange [42]. The principle of ion 
exchange is to replace CTA+ by another cation which can be further degraded. In this study, 
ammonium nitrate is used (Figure 22). 
 
 
Figure 22 Ammonium nitrate formula. 
The surfactant micelles and the inorganic network are linked by strong electrostatic interactions. A 
simple washing in solvent is not enough to remove all the surfactant. Thus NH4+, from ammonium 
nitrate, is used to replace the CTA+ in the pores.  By heating the medium, NH3 is release in the 
medium and silanol groups (Si-OH) are formed (Figure 23).     
 
 
Figure 23 Extraction of CTAB with ammonium nitrate. 
Finally the synthetization of the nanoparticles can be sum up by these two schemes (figure 24 a) and 
b)). 
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Figure 24 a) Synthesis of the nanoparticles and b) functionalization with APTES. [28], [29] 
The micelles are formed and then agglomerate to form cylinders. These latter organize themselves 
into a honeycomb structure. The silica skeleton functionalized with APTES surrounds the micelles. 
And finally, the surfactant is removed, in our case using solvent and transfer reactants and not by 
calcination. This could affect the functionalization.   
 
2) Drug loading and release study 
The loading is performed as followed, the drug is dissolved in a solvent under stirring and 
nanoparticles are added. Adsorption phenomenon allows the drug to load inside the pores of the 
particles. [10], [21], [22], [23], [24]  
The characterization of nanoparticles is performed by several techniques reported such as: UV-vis 
spectrophotometry, differential scanning calorimetry (DSC), thermogravimetric analysis (TG), 
scanning electron microscopy (SEM), transmission electron microscopy (TEM), IR Fourier transform 
Spectroscopy (FTIR) and X-ray powder diffraction (XRPD).  
The characterization can be carried out at different steps, before the loading, during the loading or 
after the loading, to follow as close as possible the process.   
 
The release is processed in vitro. Loaded nanoparticles are plunged into a buffer, as a dissolution 
medium, under stirring.  
 The characterization is performed by several techniques reported such as: UV-vis spectroscopy, DSC. 
A sorptometer is used to access surface area, pore volume and micropores size.   
 
A kinetics study of the release has been done by fitting zero-order (Eq 8), first-order (Eq 9) and 
Hixson-Crowell formula (Eq 10) with experimental data [30].   
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                                                                       𝑄 = 𝑄0 + 𝐾0𝑡                                                                         (Eq 8)                                                                                                
                                                             𝑙𝑛𝑄 = 𝑙𝑛𝑄0 + 𝐾1𝑡                                                                        (Eq 9)                           
                                                               𝑄1/3 = 𝑄0
1/3
− 𝐾𝑐𝑡                                                                      (Eq 10)                                                                              
where 𝑄 is the amount of drug dissolved at time t, 𝑄0 is the initial amount of drug in solution at t=0, 
𝐾0 is the zero-order release constant, 𝐾1is the first order release constant and 𝐾𝑐 is the cube root law 
release constant [30]. 
It was demonstrated that the dissolution rate of nifedipine was increased up to 37 times compared 
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2. Aims of the project 
 
The aims of the project are the followings: 
1. Synthesis of nanoparticles.  
 
2. Study the loading of nanoparticles with the nifedipine. Compare the loading methods: 
evaporation and washing.  
 
3. Characterize the loading with Fourier Transform spectroscopy (FTIR) and Thermogravimetric 
analysis (TGA).  
 
4. Study the release of nifedipine. Compare different methods: dialysis, USP apparatus and 
tubes. 
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3. Materials and Methods 
3.1. Synthesis 
The synthesis of nanoparticles is composed of several steps.   
The first one is the heating of 960 mL of deionized water with 2 grams of CTAB (surfactant used as a 
template of the nanoparticles) up to 80°C under magnetic agitation. After that 7 mL of 2M NaOH 
(catalyst) is added. While the mixture is under stirring and has attained 80°C, 9mL of TEOS (precursor) 
and 2 mL of APTES (functionalization) are mixed together and then added drop by drop in the bottle.  
It is possible to have different nanoparticles by varying the amount of APTES (1, 2 or 3 mL). In a 
previous study, the synthetization and the characterization of these different nanoparticles have 
been achieved. It has been decided to continue the study with 2 mL of APTES because the 
corresponding nanoparticles (MSN-2-NH2) showed the best results (see previous work, TFM Florine 
Bodet-dubin, 2016). 
The mixture is kept under magnetic agitation for 2 hours (figure 25). After that the bottle is cooled 
down to room temperature and finally closed and stored in a cabinet.  
 
Figure 25 Synthesis of the nanoparticles a) before TEOS hydrolysis b) after TEOS hydrolysis. 
After one week, the nanoparticles have decanted and are in the form of gel. The latter is filtered to 
remove all the supernatant. A Buchner filtration system is used with a membrane filter of 0.2µm. 
Once done, the gel is recovered in a beaker and placed in oven at 80°C for 24 hours.  
After the drying time, the sample is recovered and crushed with a mortar in order to have 
nanoparticles in fine powder. At this step, the nanoparticles are formed but their pores are still full of 
surfactant. The next step is the purification of the nanoparticles.  
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3.2. Purification 
Three different steps are followed to purify the nanoparticles.   
1.5 g of nanoparticles are placed in a screw cap bottle with first 100 mL of deionized water.  The 
mixture is placed under magnetic agitation and then filtered with a Buchner system (Figure 26). The 
residue is replaced in the bottle with new water and replaced under agitation.  
 
Figure 26 Buchner system and bottles of nanoparticles with deionized water under continuous stirring. 
The nanoparticles are filtered three times after three washings with deionized water, three times 
after three washings with ethanol. And the last three ones are proceeded with 150 mL of methanol 
and 1.5 mg of ammonium nitrate, the all under magnetic stirring at 60°C for 24H.  
After these steps, a powder of nanoparticles without surfactant is obtained. 
However, to ensure that the purification has been efficient enough and no CTAB or ammonium 
nitrate left in the pores of the nanoparticles, a FTIR analysis has be achieved.  
3.3. Loading 
Method A  
First of all, 60 mg of nifedipine are dissolved in 20 mL of anhydrous methanol in a 50-mL falcon tube 
covered with aluminum foil to prevent photodegradation of the drug. The mixture is placed under 
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ultra sounds for 5 min at an intensity of 10% in a cold-water bath (to prevent heat sensitivity of the 
drug). After that 160 mg of nanoparticles are added in the tube and placed 15 min under ultra sounds 
in the same cold-water bath. The tube is left under magnetic agitation for 24 hours (Figure 27). 
Finally, the tube is kept in the fridge sealed with parafilm.   
 
 
Figure 27 Schematic of the different steps of the Method A. 
 
Method A + washing 
A step of washing is added to the previous steps.  
The tube from Method A is recovered and is shaken to resuspend the nanoparticles. The mixture is 
separated into 2 tubes (15-mL falcon tubes covered with Aluminum foil, easier to centrifuge) and the 
volume is adjusted to 10 mL.  
Then the two tubes are centrifuged for 5 minutes at 1000 rpm. The supernatant is removed with a 
Pasteur pipette (as much as possible). And it is replaced by fresh anhydrous methanol (5 mL). The 
tubes are centrifuged for 2 min at 1000 rpm and the supernatant is directly removed with a Pasteur 
pipette. Deionized water is added, up to 3 mL and the tubes are centrifuged one more time with the 
same setups. While the tubes are in the freezer (-80°C for at least 1h30) or in liquid nitrogen, holes 
are done in a cap with a syringe. Once the freezing time is finished, the tubes, with the holed caps, 
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Figure 28 Photograph of the freeze dryer. 
The day after, the tubes are recapped and stored in the fridge. 
 
 
Figure 29 Schematic of the lasts steps of the Method A with washing. 
Method B  
60 mg of nifedipine are dissolved in 20 mL of anhydrous methanol in a 50-mL falcon tube covered 
with aluminum foil to prevent photodegradation of the drug. The mixture is placed under ultra 
sounds for 5 min at an intensity of 10% in a cold-water bath (heat sensitivity of the drug). After that 
160 mg of nanoparticles are added in the tube and placed 15 min under ultra sounds in the same 
cold-water bath. The tube is left under magnetic agitation for 24 hours. Finally, the tube is kept in the 
fridge, sealed with parafilm.   
The contents of the tube (anhydrous methanol with dissolved nifedipine and loaded nanoparticles) is 
introduced in a flask and placed in the rotary evaporator (Figure 30). The setups are 50°C for the bath 
temperature and 80 rpm for the rotation. The rotary evaporator is used to enhance the loading of the 
nanoparticles. [31] 
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Figure 30 Photograph of the rotary evaporator. 
Once the evaporation of methanol is done, small amount (about 5 mL) of new anhydrous methanol is 
added to recover all the nanoparticles in the bottom of the flask and a new evaporation is proceeded 
with the same setups.    
After that, the nanoparticles are recovered with a spatula and replaced in the same tube (Figure 31). 
 
 
Figure 31 Schematic of the different steps of the Method B. 
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Method B + washing  
 
The powder is separated into 2 tubes (15-mL falcon tubes covered with Aluminum foil) and 10 mL of 
deionized water is added in each. The volume is equalized with a Pasteur pipette. The two tubes are 
centrifuged for 5 minutes at 1000 rpm. The supernatant is very light and the nanoparticles and the 
nifedipine are in the bottom of the tube. The supernatant is removed with a Pasteur pipette. 5 mL of 
anhydrous methanol are added and the tubes are once more centrifuged for 5 minutes at 1000 rpm. 
The supernatant is yellow and the nanoparticles (white) are in the bottom of the tube. The 
supernatant is removed with a Pasteur pipette, but few milliliters are left in the tube (up to 2 mL) and 
deionized water is added (up to 3 mL). The tubes are centrifuged with the same setups. After that, 
they are placed in the freezer (-80°C) horizontally for 3 hours.   
After the freezing time, the cap of each tube is replaced by parafilm with holes (done with a syringe). 
And the tubes are placed in the container of the freeze dyer.   
The parameters of the machine are a vacuum of 0,002 mBar and a temperature of -75,1°C. The tubes 
are left the whole night in the freeze dryer (Figure 32).  
The day after, the tubes are recovered, recapped and stored in the fridge. 
 
Figure 32 Schematic of the lasts steps for the Method B with washing. 
Method C  
60 mg of nifedipine are dissolved in 20 mL of anhydrous methanol in a 50-mL falcon tube covered 
with aluminum foil to prevent photodegradation of the drug. The mixture is placed under ultra 
sounds for 5 min at an intensity of 10% in a cold-water bath (heat sensitivity of the drug). After that 
160 mg of nanoparticles are added in the tube and placed 15 min under ultra sounds in the same 
cold-water bath. The tube is left under magnetic agitation for 24 hours. Finally, the tube is kept in the 
fridge sealed with parafilm.   
The contents of the tube (anhydrous methanol with dissolved nifedipine and loaded nanoparticles) is 
introduced in a flask and placed in the rotary evaporator. The setups are 50°C for the bath 
temperature and 80 rpm for the rotation. The powder is recovered with a spatula (Figure 33). 
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Figure 33 Schematic of the different steps for the Method C.  
Method C + washing  
The powder is shared in 2 falcon tubes (15 mL) with 5 mL of anhydrous methanol in each. Then the 
tubes are centrifuged for 2 minutes at 1000 rpm. The supernatant is directly removed with a Pasteur 
pipette (as much as possible). And deionized water is added, up to 3 mL. The tubes are placed in 
liquid nitrogen to be rapidly frozen and then introduced in the container of the freeze drier. The 
tubes are recovered the day after (Figure 34). 
 
Figure 34 Schematic of the lasts steps for the Method C with washing. 
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 From these different methods are obtained 4 samples: 
MSN-2-NH2-Nif Method B 
MSN-2-NH2-Nif Method B + washing 
MSN-2-NH2-Nif Method A + washing 
MSN-2-NH2-Nif Method C + washing 
After these steps of loading and washing, a FTIR analysis has been proceeded to confirm or 
not the presence of nifedipine as well as a TGA to access the quantity of nifedipine present 
in the samples.  
3.4. Release 
3.4.1.  Dialysis 
A dialysis membrane (with a cut-off of 10 KDa) has been used to study the release of a suspension of 
nanoparticles (Figure 35).  
 
 
Figure 35 Photograph of the dialysis membrane. 
To do so, the release was studied in PBS, water with a mixture of salts which has the role to mimic 
the body fluids. 
The membrane cassette is plunged in 200 mL of adjusted PBS (pH at 6.8) at 37°C and under agitation 
(Figure 36). 
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Figure 36 Photograph of the release experiment. 
First the adjusted PSB has been prepared. A pellet of PBS was dissolved and the pH adjusted with a 
solution of HCl at 1 mol/L. If the pH became too low, it was possible to rectify it with a solution of 
NaOH at 1 mol/L.  
In this study, nifedipine and loaded nanoparticles MSN-2-NH2- Nif have been used.   
In the first cassette, 1 mg of nifedipine is dissolved in 3 mL of PBS which corresponds to a 
concentration of 0.33 mg/mL.   
From a previous TGA, MSN-2-NH2-Nif (Method B) are loaded with 25.73% of nifedipine. The loading 
is done with 160 mg of nanoparticles.  
100 % – 160 mg  nanoparticles 
25.73 % → 41.168 mg nifedipine 
In 160 mg of nanoparticles, there are 41.168 mg of nifedipine.  
41.168 mg – 160 mg 
1 mg → 3.88 mg 
3.8 mg of MSN-2-NH2-Nif (Method B) have been introduced into the cassette to have an equivalent 
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2 aliquots were taken (2x1.5 mL) each time with a pipette. And the same volume of fresh PBS was 
added.  
The samples have been analyzed with the UV-vis NIR spectrophotometer.   
3.4.1. USP apparatus 
An experiment using the USP apparatus (I and II, a recapitulative table of the different types of USP 
apparatus is given in Annex A) have been carried out. The equipment is commonly used to study drug 
delivery systems (Figure 37).  
 
      
Figure 37 Photograph of the USP apparatus, the basket and the pellet. 
A pellet of MSN-2-NH2-Nif (Method B + washing) have been done with a press (8 tons for 10 
minutes) and placed in the basket of the USP. It was immerged in 250 mL of adjusted PBS. The jar was 
heated up to 37°C thanks to a water bath and under agitation thanks to the rotation of the basket 
(100 rpm).  
Aliquots of 1 mL have been taken with the help of a syringe. An equal volume of fresh PBS was then 
added (another jar contains it in order to have it at 37°C directly).  
To prevent evaporation, a piece of foam was placed on the cap and the syringe was always placed in 
the needle.   
3.4.2. Tubes 
In parallel an experiment with nanoparticles in powder form has been done in 50-mL Falcon tubes. 
This experiment models the best the final use of nanoparticles with the implant. 
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Figure 38 Photograph of the tubes experiment. 
4 tubes have been prepared: 2 with MSN-2-NH2-Nif (Method B + washing) and 2 with MSN-2-NH2-
Nif (Method A + washing).  
The tubes were covered with aluminum foil to prevent photodegradation. The equivalent of 1 mg of 
nifedipine (to be in the range of the nifedipine solubility in PBS) for each sample has been placed in 
50 mL of PBS. The tubes were placed in a water bath at 37°C under magnetic agitation (Figure 38).  
Before taking an aliquot, the tubes were centrifuged for 5 minutes at 1500 rcf. After that, an aliquot 
of 1 mL has been taken from each tube with a syringe and replace by fresh adjusted PBS.  
3.5. Baseline test 
A test of the baseline with PBS has been processed. The measurement was done with the 
spectrophotometer. The test was carried out with one cuvette (single beam measurement) filled with 
PBS at room temperature. Each hour the spectrum (200-400 nm) of PBS was taken for 14 hours. 
3.6. Characterization 
Several characterization techniques have been used during the project. The FTIR and the TGA for the 
loading; the UV-vis spectroscopy for the release and the baseline test. 
3.6.1. FTIR 
The machine used is a Fourier transform infrared spectrophotometer (Figure 39), Nicolet 6700 FT-IR. 
The source is a He/Ne laser.  
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The software used to analyze the data was OMNIC 8.   
The equipment was used in transmission mode. The number of scan was 120 and the resolution 4 
cm-1.   
The transmission mode needs a specific sample preparation. The nanoparticles (small amount) are 
mixed with KBr (solid dilution, one volume of nanoparticles for 4 of KBr) in a mortar. The fine powder 
is pressed into a pellet. The vitrification of the powder is done during the pressing which gives a 
translucent pellet (essential for the analysis).  
 
Figure 39 a) Schematic of the FTIR equipment [32], b) Photograph of the FTIR equipment. 
The spectra were analyzed with the help of a table (Annex B) and previous work (see previous work, 
TFM Florine Bodet-dubin, 2016). 
The infrared spectroscopy is based on the interaction between an electromagnetic beam and the 
matter. Thanks to the low energy, it enables to access the vibrational modes of atoms and molecules, 
and the environment of some functional groups.   
The infrared spectrum of a substance can be seen as its fingerprint. Here the infrared spectroscopy is 
used as a qualitative analysis.  
3.6.1.  TGA 
The machine used is a thermogravimetric analyzer TA instruments Q5 (Figure 40). 
The software used to analyze the data is Universal Analysis.   
The sample (powder) is put in the cruiser. The latter is weighted before and after being filled, thus the 
mass of the sample is known. 
The setups of this experiment are the following: 
 Equilibrate at 30,00°C 
 Isothermal for 2,00 min 
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 Ramp 10,00°C/min to 800°C 
with a nitrogen flux of 60 mL/min.  
 
  
Figure 40 a) Schematic of the TGA equipment [33], b) Photograph of the TGA equipment. 
The principle of the TGA is to measure the mass variation of a material as a function of time or 
temperature, in a controlled atmosphere. The sample, supported by the balance, is heated in a 
furnace under inert gas. 
The TGA analysis is used as a quantitative analysis. 
3.6.2. UV-vis spectroscopy 
The equipment used is a UV-vis NIR spectrophotometer (Figure 41), Shimadzu UV-3600. The sources 
are a deuterium lamp for the UV wavelengths and a tungsten lamp for the visible and IR wavelengths. 
The software used to analyze the data was UV Probe Ver 2.31 Shimadzu.   
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Figure 41 a) Schematic of the principle of the double beam spectrophotometer [34], b) Photograph of the UV-vis NIR 
equipment. 
The software was used in two different modes during this work: photometric (238, 288 and 338 nm) 
and spectrum mode (from 200 to 400 nm).   
The photometric mode enables to do measurement at specific wavelengths in the spectrum. A 
specificity of the software is the 3-wavelength quantitation using this mode. It enables to eliminate 
the effects of interfering components. This formula is given as the final absorbance: 
A= A2(λ1- λ3)-A3(λ1- λ2)-A1(λ2- λ3) 
Where A1, A2 and A3 are the absorbance of the sample at λ1, λ2 and λ3 respectively. The wavelength 
λ2 corresponds to the target wavelength.  [35]  
A typical UV-vis spectroscopy analysis follows these steps: 
1. Plot the absorption spectrum of the substance to be analyzed to choose the working 
wavelength. It is chosen at the maximum of absorption to reduce the position of the 
repeatability error (Figure 42). 
 
Effect of Loading and Release Factors In Vitro of Mesoporous Silica Nanoparticles as Drug Carriers for Nifedipine   
  39 
 
 
Figure 42 Graph which emphasizes the repeatability error.[34] 
  
2. Adjust the wavelength at the working wavelength. 
3. Do a calibration curve with standards (at least 5 with the blank). The blank is the solution 
used without the substance to dose. The calibration curve allows to access the molar 
attenuation coefficient, ελ, at one wavelength thanks to the slope of the curve (linear, if the 
blank is included). 
4. Measure the samples absorbance regarding the blank. 




                                                                     (𝐸𝑞 11) 
The UV-vis spectroscopy is based on the interaction between an electromagnetic beam and the 
matter. The energy can reach the energy level required for the excitation of atoms, this method 
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4. Results and discussion 
4.1. Purification 
4.1.1. FTIR 
An infrared analysis has been processed to ensure that the nanoparticles were enough washed and 
there was no more CTAB nor ammonium nitrate (Figure 43). The step of purification is to remove 
CTAB with the help of ammonium nitrate. But for the future it is important that both CTAB and 
ammonium nitrate have been eliminated during this process.  
 
Figure 43 FTIR spectra of CTAB (blue curve), clean nanoparticles (purple curve), ammonium nitrate (green curve) and 
dirty nanoparticles (red curve) 
The purple curve corresponds to clean nanoparticles. The band at 3439 cm-1 and the peak at 961 cm-1 
correspond to silanol (Si-OH), the peak at 1630 cm-1 correspond to amine (R-N-H2), the peak at 1384 
cm-1 corresponds to alkane (C-C), the band at 1083 cm-1 and the peaks at 799 and 464 cm-1 
correspond to Si-O-Si. 
Whereas the red curve shows us dirty nanoparticles. We can see that the red curve is affected by the 
green one (ammonium nitrate) but not by the blue one (CTAB).  
If we compare the purple curve with the red one we can see that the band at 3439 cm-1 is shifted to 
3128 cm-1. At 1384 cm-1, a peak appears and the band of Si-O-Si is dramatically reduced as well as the 
peak at 457 cm-1. These changes are due to the presence of ammonium nitrate. In the red curve, we 
recognize three different peaks of ammonium nitrate, the band at 3136 cm-1 (which causes the shift), 
the peak at 1381 cm-1 (which is predominant on the band of Si-O-Si at 1091 cm-1 and 457 cm-1 ) and 
the last one at 825 cm-1. 
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However we do not see any influence of the bleu curve on the red one. In this case, the nanoparticles 
were polluted by ammonium nitrate but not by the CTAB. 
Regarding these results, nanoparticles have been washed one more time only in anhydrous methanol 
at 60°C for 24 hours. A new FTIR analysis has been processed after this washing to ensure the 
cleanliness of the nanoparticles. 
4.2. Loading  
4.2.1. FTIR  
Another infrared analysis has been carried out to check the presence of nifedipine after the loading 
of nanoparticles (Figure 44).  
 
Figure 44 FTIR spectra of unloaded nanoparticles (pink curve), loaded nanoparticles (red curve) and nifedipine (green 
curve). 
The green curve corresponds to nifedipine, the pink curve is the spectrum of unloaded nanoparticles 
and the red one of loaded nanoparticles.  
On the red curve, we can recognize peaks of nifedipine for example at 3332 cm-1, at 2953 cm-1 and at 
1679 cm-1. In the region below 1700 cm-1, a multitude of peaks of the nifedipine are reported on the 
spectrum of loaded nanoparticles.  
The curve of unloaded nanoparticles is modulated by the curve of nifedipine and gives the curve of 
loaded nanoparticles.  
A last infrared analysis has been done to emphasize the difference between two methods (Method 
B+ washing and Method A + washing, Figure 45).  
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Figure 45 FTIR spectra of MSN-2-NH2-Nif (Method B + washing) (green curve) and MSN-2-NH2-Nif (Method A+ washing) 
(red curve). 
The two curves are obtained with two different methods, in the case of the green curve (Method B + 
washing), the loading has been achieved with 2 sessions of rotary evaporator and washing whereas in 
the case of the red curve (Method A + washing), no session of evaporation and one washing have 
been done.   
The green curve can be compared with the previous red curve of loaded nanoparticles. The same 
peaks, due to the presence of nifedipine, are found in both curves. However, here, the red curve 
(MSN-2-NH2-Nif Method A + washing), shows that much smaller nifedipine peaks. It shows that in 
the case of the Method A + washing there is less nifedipine than in the Method B + washing. This can 
be explained by the presence or not of the rotary evaporation sessions which enhance the loading.   
4.2.2 TGA  
A thermogravimetric analysis has been processed to have a quantitative measurement of the 
nifedipine present with the nanoparticles (Figure 46). 
With this analysis, it is possible to access the percentage of loading thanks to the following formula 
[36]. 
𝑁𝑖𝑓𝑒𝑑𝑖𝑝𝑖𝑛𝑒 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 =  
% 𝑚𝑎𝑠𝑠 𝑙𝑜𝑠𝑠 𝑙𝑜𝑎𝑑𝑒𝑑 𝑠𝑎𝑚𝑝𝑙𝑒𝑠 − % 𝑚𝑎𝑠𝑠 𝑙𝑜𝑠𝑠 𝑒𝑚𝑝𝑡𝑦 𝑠𝑎𝑚𝑝𝑙𝑒𝑠
% 𝑚𝑎𝑠𝑠 𝑙𝑜𝑠𝑠 𝑝𝑢𝑟𝑒 𝑑𝑟𝑢𝑔
∗ 100 
The four samples have been tested. 
 
 
Effect of Loading and Release Factors In Vitro of Mesoporous Silica Nanoparticles as Drug Carriers for Nifedipine   
  43 
 
Figure 46 TGA curves of MSN-2-NH2, MSN-2-NH2-Nif (Method B, Method B + washing, Method A + washing and Method 
C + washing) 
The mass loss of MSN-2-NH2 is due to the functionalization with APTES. 
The four curves, blue, orange, grey (under the yellow curve) and yellow are the nanoparticles loaded 
with the different methods, respectively, the Method B, Method B + washing, Method A + washing 
and Method C + washing. Here, the influence of the method on the final amount of nifedipine is 
clearly visible. 
The blue curve shows the higher quantity of nifedipine. It can be explained because the loaded 
nanoparticles have just been treated with the rotary evaporator. Only the methanol was evaporated 
and all the nifedipine not loaded inside the nanoparticles stayed there. So in this measurement, the 
mass loss corresponds to the nifedipine which is inside and outside of the pores.  
The orange curve shows a less important mass loss than the blue one. It can be explained by the 
removal of the supernatant. A part of the nifedipine unloaded has been removed.  
The grey and yellow curves are above the MSN-2-NH2 curve. Here, it seems that there is no 
nifedipine in the samples. The difference with the two previous curves is the removal of the 
supernatant.  
In the Method A + washing (grey curve), the supernatant was removed and the nanoparticles directly 
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evaporated with the rotary evaporator, the nanoparticles recovered and plunged in fresh methanol. 
The supernatant was removed and the nanoparticles freeze dried. 
With two different methods, two similar curves are obtained. 
The percentage of loading has been calculated for each sample (Table 3), the detailed calculations are 
given in annexes (Annex C).   
Table 3 Loading percentage of each sample. 
  Method B 
Method B + 
washing 
Method A + 
washing 
Method C + 
washing 
% loading  26.86 21.28 2.97 3.12 
 
It can be seen with the Method A + washing and C + washing that a very small amount of nifedipine is 
present. The fact that the grey and yellow curves are above the unloaded nanoparticles can be due to 
humidity (present in unloaded particles and less in loaded nanoparticles).  
The loading has been done with 60 mg of nifedipine with 160 mg of nanoparticles. The nifedipine 
represents 37.5% of the weight of the nanoparticles. In the method B, all the nifedipine is recovered 
with the nanoparticles. However, with the TGA, we can see that only 26.86% is present. A difference 
of 10,64 mg left. It may be because of the recovery of the powder from the flask (loss of sample). Or 
it can be because of the homogenization of the powder. If it is not well homogenized, more 
nanoparticles can be taken for the measurement and modify a bit the percentage.  
4.3. Release  
4.3.1. UV-vis Spectroscopy 
Calibration curve 
The calibration curve (Figure 47) has been obtained from a solution of nifedipine in PBS at 4 µg/mL at 
room temperature and dissolutions. The curve has been fitted with a linear one. The solubility of 
nifedipine in PBS is 5.6 µg/mL. 
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Figure 47 Graph of the calibration curve. 
The calibration curve gives the absorbance as a function of the concentration at 238 nm. 
Dialysis release  
Here are the results of the dialysis experiment (Figures 48 and 49). 
The first experiment was done with nifedipine as a control experiment.  
 
Figure 48 Evolution of the concentration with time for the Dialysis release study. 















































Average concentration vs time at 238 nm
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The concentration of nifedipine increases with time. It can be said that there is a release. The biggest 
quantity of released nifedipine is between 360 and 1440 minutes. After 1440 minutes, it increases a 
bit. It is possible that the release of nifedipine was not finished. The drug had two barriers to pass 
through to be released: the nanoparticles and the membrane. So the release can be slow.  
The highest concentration reached by nifedipine is 5.29 mg/L.  But the initial concentration in the 
membrane was 333 mg/L which is much higher than the concentration in the release medium. It is 
possible that the membrane was not adapted to the drug and retained it. 
Here are the results for the study of nanoparticles in the membrane. This was done with the Method 
B. The nanoparticles were used in powder-form.  
 
Figure 49 Evolution of the concentration with time for the Dialysis release study. 
The concentration slowly increases from the first point to 360 minutes. And then a high increase of 
the concentration is seen from 360 to 1440 minutes. After this time, the concentration of nifedipine 
decreases. As the concentration of the nifedipine increases, it can be said that there is a release.  
The highest concentration reach by the nifedipine is 8.15 mg/L.    
USP release  
Here are the results for the study of nanoparticles in the USP apparatus (Figure 50). This was done 
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Figure 50 Evolution of the concentration with time for the USP release study. 
The concentration of nifedipine increases until 2880 minutes and then decreases. As there is an 
increase of the nifedipine concentration in the release medium, it can be said that there is a release.  
The highest concentration attained by the nifedipine is 9.20 µg/mL.  
Tubes release  
Here are the results of the release of nanoparticles introduced in falcon tubes. This was done with 
the Method B + washing (Figure 51) and Method A + washing (Figure 52). The nanoparticles were 
used in powder form. 
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The concentration of nifedipine, in the release medium, increases rapidly until 120 minutes and then 
increases more slowly until 2880 minutes to finally decrease.  
The higher concentration of the released nifedipine is 10.94 µg/mL. 
The concentration of nifedipine increases more rapidly than with the dialysis and the USP. It can be 
due to the higher agitation (magnetic agitation for the tubes, rotation of the basket for the USP 
apparatus and magnetic agitation in the beaker where the membrane is immersed) in the tubes 
which provokes a faster release. And the drug has only one barrier, the nanoparticle. 
It is possible to compare this results with those from the USP because the same sample is used. In 
both cases there is a release but the highest concentration for the USP is 9.20 µg/mL whereas for the 
tubes it is 10.94 µg/mL.  
 
Figure 52 Evolution of the concentration with time for the Tube release study. 
The concentration of nifedipine, in the release media, increases rapidly until 120 minutes. After this 
time, a decrease is monitoring following by an increase until 2880 minutes. After that the 
concentration decreases. 
The highest value of concentration attained is 1.64 µg/mL.  
Baseline test 
A baseline test has been achieved to check the time stability and reproducibility (Figure 53). The 
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Figure 53 Evolution of the absorbance with the wavelengths for the baseline test. 
The absorbance is not equal to zero with time, so the baseline is not stable. On the figure 53, the 
absorbance is gradually increasing with time. The first measurements are quite similar, then 
absorbance increases and stabilizes for the lasts ones.  
Normally, the baseline measurements should be the same. One hypothesis is an energy change of 
the lamp between each measurement. It is possible that the lamp does not emit with the same 
energy (and the same intensity) during the whole experiment. As the absorbance depends on the 
intensity emitted by the lamp, it can result in fluctuations of the baseline.  
This behavior of the baseline can explain some high error bars in the release results. It could also 
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5. Conclusion 
The synthesis of nanoparticles with 2 mL of APTES have been achieved. They have been loaded 
following different methods: Method B, Method B + washing, Method A + washing and Method C + 
washing. In these different methods, the number of rotary evaporation sessions varied as well as the 
washing of the loaded nanoparticles.  
Afterwards the release of these nanoparticles from the different methods have been studied using 
the dialysis, the USP apparatus and falcon tubes. The results of these three methods have been 
compared to choose one of the method (table 4).   
 
Table 4 Summary table of the project. 
  Rotary evaporator Washing TGA Release concentration 
Method B 2 No 26.86% 8.15 mg/L (Dialysis) 
Method B + washing 2 Yes 21.28% 
9.20 mg/L (USP)  
10.94 mg/L (Tube) 
Method A + washing 0 Yes 2.97% 1.64 mg/L (Tube) 
Method C + washing 1 Yes 3.12% x 
 
The method B shows the higher amount of nifedipine (26.86%) with 2 sessions of evaporation and no 
washing.  
When washing is added (Method B + washing), the amount of nifedipine is a bit decreased (21.28%), 
possibly because of the removal of the nifedipine which is not on the surface of the nanoparticles or 
in the pores.   
When there is no evaporation and only a removal of the supernatant (Method A + washing) the 
quantity of nifedipine is dramatically decreased (to 2.97%), possibly because of the lack of the 
evaporation which enhance the loading.   
And when an evaporation is added to the process (Method C + washing), the amount of nifedipine is 
a little higher than in the Method A + washing.  
The better solution for the loading is the Method B + washing. In this process the loaded is enhanced 
thanks to the 2 sessions of evaporation and the residual nifedipine is removed by the washing. 
Effect of Loading and Release Factors In Vitro of Mesoporous Silica Nanoparticles as Drug Carriers for Nifedipine   
  51 
For the release, the Method B attains 8.15 mg/L which is few comparing with the initial concentration 
in the membrane. A possible explanation is that the membrane is not adapted to the drug and retains 
it.  
Concerning the Method B + washing, the higher concentration reached during the USP experiment is 
9.20 mg/L whereas with the tubes it is 10.94 mg/L. The concentrations are in the same range and the 
slight difference can be explain with the baseline test. As the baseline seems to change in a small 
range of absorbance, the results of the release study can be affected by small fluctuations. Another 
explication which should be taken into account is the form of the nanoparticles in each experiment. 
In the USP experiment, a pellet is done and the nanoparticles are compacted whereas with the tubes, 
they are in powder-form. In the pellet, it can be more difficult for the drug to be released. 
With the Method A, the higher concentration obtained is 1.64 mg/L. The value is smaller than in the 
other release studies. But this is relevant regarding the TGA results.  
Finally, the dialysis is excluded since it may retain the drug.   
The results from the Method B + washing show comparable results between the USP and the tube. 
The tubes are the privilege solution because they are more easily used and less expensive than the 
USP apparatus. 
 
By taking into consideration the results of the loading the Method B + washing is taken on. And 
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6. Further work  
To follow this project, the next step which could be planned is the study of nifedipine loading and 
release from nanoparticles attached to titanium. The way to bind nanoparticles to titanium will not 
be explained here (see TFM Paul Game, 2017).  
Loading 
The sample will be received already covered with nanoparticles. It will be plunged in a solution of 
anhydrous methanol and nifedipine. For the loading of nanoparticles, a solution at 4 µg/mL was used 
for 160 mg of nanoparticles. In the case of the titanium samples, the nifedipine concentration can be 
lowered because the nanoparticles concentration will be lower.   
The mixture will be kept under orbital agitation for 24 hours in a cold-water bath and covered with 
Aluminum foil to prevent the photodegradation of the nifedipine. 
Considering the results of this project, it could be better to evaporate the methanol with the rotary 
evaporator. But, the stability of the sample (the sample must not turn over) in the flask must be 
certain not to alter the coating, as well as the thermal stability of the coating. 
After the loading, the sample can be washed with a quick immersion in fresh anhydrous methanol 
and dried with nitrogen. 
A possible way to characterize the loading could be to do an infrared spectrum of the sample via an 
ATR measurement. 
Release 
The release of the nifedipine will be done in adjusted PBS.   
The sample can be plunged in a beaker with adjusted PBS and under orbital agitation. It must be 
protected from the light. The use of the USP apparatus can be considered because it allows the 
agitation and the heating of the medium at the same time. 
For the characterization, the use of HPLC could be considered as the concentration of nifedipine may 
be low.  However, the use of the UV-vis spectroscopy remains possible if the release medium volume 
is not too high (prevention of a too high dilution of the nifedipine whose concentration could be 
difficult to measure).   
Nevertheless, independently of the method (HPLC or UV-vis spectroscopy) chosen, the concentration 
measurement should be done directly after having taken the aliquot.  
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7. Economic analysis 
 
Table 1 Costs associated to the synthesis of nanoparticles. 
Material Quantity Price Cost (€) 
NaOH 8 g 16.30€/kg 0.13 
Distilled water 3.84 L 0.08€/L 0.31 
CTAB 8 g 302.10€/g 2416.8 
TEOS 36 mL 74.80€/L 2692.8 
APTES 9 mL 53.50€/ 100mL 4.82 
Total cost associated to the synthesis of 
nanoparticles 
  5122.06 
 
Table 2 Costs associated to the purification of nanoparticles. 
Material and equipment Quantity Price Cost (€) 
Distilled water 1 L 0.08€/L 0.08 
Ethanol 1 L  25.50€/L 25.5 
Methanol 1.5 L 31.75€/L 47.62 
Ammonium nitrite 15 g 87.5 €/kg 1.31 
Total cost associated to the purification 
of nanoparticles 
  74.51 
 
  Memoria 
54   
Table 3 Costs associated to the loading of nanoparticles. 
Material and equipment Quantity Price Cost (€) 
Nifedipine 0.6 g 54.00€/g 32.4 
Anhydrous methanol 200 mL 59€/L 11.8 
Freeze dryer 10 5€ / sample 50 
Total cost associated to the loading of 
nanoparticles 
  94.2  
 
Table 4 Costs associated to the release of nanoparticles. 
Material and equipment Quantity Price Cost (€) 
PBS 5 L 30€/500mL 300 
Dialysis membranes 2 113€/ 10 cassettes 22.6 
USP apparatus 1 200€/ essay 200 
Total cost associated to the release of 
nanoparticles 
  522.6 
 
Table 5 Costs associated to the characterization of nanoparticles. 
Equipment Quantity Price Cost (€) 
UV-vis spectroscopy 15 h 4.85€/h 72.75 
FTIR 5 h 5.14€/h 25.7 
TGA 6 60€/sample 360 
Total cost associated to the 
characterization of nanoparticles 
  458.45 
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Table 6 Costs associated to human resources and others. 
Resources Hours Price Cost (€) 
PhD 60 60€/h 3600 
PhD student 100 30€/h 3000 
Project student 400 20€/h 8000 
Others (gloves, pipettes, boxes…)   250 
Total cost associated to human 
resources and others 
  14850 
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8. Environmental impact 
 
The environmental impact has been considering during all steps of this project. The reactants were 
used in small quantities to prevent waste.  
All the wastes are treated differently regarding their nature. There are different trashes for the 
solvents used (acids, bases, polar, non-polar). For specific chemical wastes, containers are provided 
to the laboratory personal. The name of the waste is written on the container and is treated apart 
from others. The identification and the follow-up of chemical wastes are very important. Once the 
containers are full, they are stored in a cabinet.  
 
There are also different trashes for the solid wastes (non-contaminated wastes and contaminated 
ones). Selective sorting is also done in the laboratory. There are different trashes for paper, plastics 
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9. Annexes 
9.1. Annex A  
The following table gives a recap of the different USP apparatus. [37] 
Name  Rotation speed Medium volume Used for 
Apparatus I Rotating basket 
 
 
50-120 rpm 500-4000 mL 
• Immediate release. 
• Delayed release. 
• Chewable tablets. 
• Extended release 
tablets and floating 
dosage form. 





25-50 rpm 500-4000 mL 
• Immediate release. 
• Orally disintegrating 
tablets. 
• Chewable tablets. 
• Delayed release. 
• Extended release 
tablets, capsules and 
suspension. 
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6-35 rpm 250 mL 
• Controlled release 
formulations 
• Chewable tablets. 
Apparatus IV Flow through cell 
 
 Up to 3L per hour 
• Drug product 
containing poorly 
soluble API. 
• Powder and granules. 
• Microparticles. 




25-50 rpm 500-4000 mL 
• Transdermal patches. 
• Ointment. 
• Floaters and emulsions. 
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Apparatus VI Rotating cylinder 
 
 
25-50 rpm 500-4000 mL 
• Transdermal patches. 




30 rpm Variable 
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9.2. Annex B 
Here is the table used to analyze the infrared spectra (figure 54). 
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9.3. Annex C 
Here are the detailed calculations which have been done to calculate the loading percentage of 
nifedipine in the nanoparticles.  
 
𝑁𝑖𝑓𝑒𝑑𝑖𝑝𝑖𝑛𝑒 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 =  
% 𝑚𝑎𝑠𝑠 𝑙𝑜𝑠𝑠 𝑙𝑜𝑎𝑑𝑒𝑑 𝑠𝑎𝑚𝑝𝑙𝑒𝑠 − % 𝑚𝑎𝑠𝑠 𝑙𝑜𝑠𝑠 𝑒𝑚𝑝𝑡𝑦 𝑠𝑎𝑚𝑝𝑙𝑒𝑠
% 𝑚𝑎𝑠𝑠 𝑙𝑜𝑠𝑠 𝑝𝑢𝑟𝑒 𝑑𝑟𝑢𝑔
∗ 100 
 
• Nifedipine  
% mass loss = 100.09 - 5.48= 94.61 % 
 
• MSN-2-NH2 
% mass loss = 92.83 – 76.05 = 16.78 % 
 
• MSN-2-NH2-Nif Method B 
% mass loss = 96.23 - 54.03 = 42.20 % 
 
• MSN-2-NH2-Nif Method B + washing 
% mass loss = 97.89 – 60.98 = 36.91% 
 
• MSN-2-NH2-Nif Method A + washing 
% mass loss = 96.67 – 77.08 = 19.59% 
 
• MSN-2-NH2-Nif Method C + washing 




Nifedipine loading:  
 
• MSN-2-NH2-Nif Method B 
42.2 − 16.78
94.61
∗ 100 = 26.86 %  
 
• MSN-2-NH2-Nif Method B + washing 
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36.91 − 16.78
94.61
∗ 100 = 21.27 % 
 
• MSN-2-NH2-Nif Method A + washing 
19.59 − 16.78
94.61
∗ 100 = 2.97 % 
 
• MSN-2-NH2-Nif Method C + washing 
19.73 − 16.78
94.61
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